agilon health, inc. (AGL) experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.
While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.
However, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.